Handling Worker and Third-Party Exposures to Nanotherapeutics During Clinical Trials

Authors

  • Gurumurthy Ramachandran,

    1. Professor in the Division of Environmental Health Sciences at the School of Public Health at the University of Minnesota in Minneapolis, MN.
    Search for more papers by this author
  • John Howard,

    1. Director of the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services.
    Search for more papers by this author
  • Andrew Maynard,

    1. Director of the Risk Science Center; the Charles and Rita Gelman Risk Science Professor; and a Professor Environmental Health Sciences at the School of Public Health at the University of Michigan.
    Search for more papers by this author
  • Martin Philbert

    1. Dean of the School of Public Health and a Professor of Toxicology at the University of Michigan.
    Search for more papers by this author

Abstract

The article focuses on issues relating to occupational exposures of researchers and lab workers, and exposures of bystanders such as health care workers and family members during HSR using nanomaterials. Such third-party exposures give rise to unique challenges relating to oversight as well as exposures to worker groups not previously studied. Given the current state of knowledge regarding health risks from such exposures, a more precautionary approach to oversight seems advisable.

Ancillary